NextCure (NXTC) Competitors

NextCure logo
$0.70 -0.06 (-7.53%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$0.72 +0.03 (+3.98%)
As of 02/12/2025 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NXTC vs. AVTX, CLSD, IGMS, GALT, RANI, ALTS, PYXS, KPTI, ASRT, and INCR

Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Avalo Therapeutics (AVTX), Clearside Biomedical (CLSD), IGM Biosciences (IGMS), Galectin Therapeutics (GALT), Rani Therapeutics (RANI), Janone (ALTS), Pyxis Oncology (PYXS), Karyopharm Therapeutics (KPTI), Assertio (ASRT), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

NextCure vs.

NextCure (NASDAQ:NXTC) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.

NextCure presently has a consensus price target of $4.00, suggesting a potential upside of 474.47%. Avalo Therapeutics has a consensus price target of $40.00, suggesting a potential upside of 420.83%. Given NextCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe NextCure is more favorable than Avalo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Avalo Therapeutics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

NextCure received 74 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.52% of users gave NextCure an outperform vote while only 33.33% of users gave Avalo Therapeutics an outperform vote.

CompanyUnderperformOutperform
NextCureOutperform Votes
80
64.52%
Underperform Votes
44
35.48%
Avalo TherapeuticsOutperform Votes
6
33.33%
Underperform Votes
12
66.67%

42.7% of NextCure shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 13.3% of NextCure shares are held by insiders. Comparatively, 0.3% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NextCure has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

In the previous week, NextCure had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 2 mentions for NextCure and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.87 beat NextCure's score of 0.94 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
NextCure Positive
Avalo Therapeutics Very Positive

NextCure's return on equity of -62.50% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NextCureN/A -62.50% -53.67%
Avalo Therapeutics N/A -442.16%122.99%

Avalo Therapeutics has higher revenue and earnings than NextCure.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NextCureN/AN/A-$62.72M-$2.09-0.33
Avalo Therapeutics$1.92M41.56-$31.54MN/AN/A

Summary

NextCure beats Avalo Therapeutics on 7 of the 13 factors compared between the two stocks.

Get NextCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXTC vs. The Competition

MetricNextCurePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$22.12M$6.86B$5.65B$9.04B
Dividend YieldN/A2.90%5.31%4.00%
P/E RatioN/A8.9988.1218.99
Price / SalesN/A311.371,013.0178.41
Price / CashN/A75.4646.0938.87
Price / Book0.175.535.135.00
Net Income-$62.72M$123.50M$113.24M$222.75M
7 Day Performance-11.86%-3.29%-1.39%-1.01%
1 Month Performance-10.50%-0.08%4.85%4.04%
1 Year Performance-47.25%5.40%25.24%21.71%

NextCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXTC
NextCure
4.5101 of 5 stars
$0.70
-7.5%
$4.00
+474.5%
-49.5%$22.12MN/A0.0090Short Interest ↑
News Coverage
Gap Up
High Trading Volume
AVTX
Avalo Therapeutics
3.6935 of 5 stars
$7.96
-2.7%
$40.00
+402.5%
+58.7%$82.70M$1.92M0.0040Positive News
CLSD
Clearside Biomedical
2.0609 of 5 stars
$1.09
-3.5%
$5.33
+389.3%
-25.4%$82.67M$8.23M-2.4230High Trading Volume
IGMS
IGM Biosciences
4.8242 of 5 stars
$1.38
-2.8%
$5.50
+298.6%
-92.0%$82.06M$2.13M-0.38190
GALT
Galectin Therapeutics
1.2672 of 5 stars
$1.30
-0.8%
$11.00
+746.2%
-21.1%$81.59MN/A-1.789
RANI
Rani Therapeutics
3.58 of 5 stars
$1.42
-6.6%
$12.33
+768.5%
-52.7%$81.35MN/A-1.34110Gap Up
ALTS
Janone
N/A$5.74
-1.2%
N/AN/A$80.76M$39.61M0.00170Positive News
PYXS
Pyxis Oncology
2.9572 of 5 stars
$1.33
-5.0%
$9.20
+591.7%
-73.0%$79.10MN/A-1.2960Positive News
KPTI
Karyopharm Therapeutics
3.846 of 5 stars
$0.62
-1.3%
$5.00
+702.7%
-54.9%$78.60M$148.44M-0.55380Analyst Forecast
News Coverage
ASRT
Assertio
3.4105 of 5 stars
$0.82
+2.3%
$3.25
+296.3%
-0.2%$78.29M$152.07M-1.1220Short Interest ↓
News Coverage
Positive News
INCR
InterCure
1.184 of 5 stars
$1.72
+0.3%
N/A-7.8%$78.15M$96.61M0.00350News Coverage
Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:NXTC) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners